Larimar Therapeutics (LRMR) EPS (Basic) (2013 - 2025)
Larimar Therapeutics (LRMR) posted EPS (Basic) of -$6.87 for Q4 2025, down 961.66% on a QoQ basis from -$0.65 in Q3 2025, and down 105.98% year-over-year from $114.96 in Q4 2024.
Larimar Therapeutics (LRMR) EPS (Basic) (2013 - 2025) Analysis & Trends
Larimar Therapeutics' EPS (Basic) history runs 13 years deep, the most recent figure standing at -$6.87 for Q4 2025.
- Quarterly EPS (Basic) fell 105.98% year-over-year to -$6.87 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$19.13 (down 301.13% YoY) and the FY2025 annual result came in at -$18.25, down 323.49% from the prior year.
- EPS (Basic) was -$6.87 for Q4 2025 at Larimar Therapeutics, down from -$0.65 in the prior quarter.
- Across five years, EPS (Basic) topped out at -$0.22 in Q1 2023 and bottomed at -$7.75 in Q4 2021.
- A 5-year average of -$1.85 and a median of -$0.63 in 2022 frame the typical range for EPS (Basic).
- Annual changes were most pronounced in 2023 — EPS (Basic) soared 76.71% — and 2024, when it slumped 134.44%.
- Larimar Therapeutics' EPS (Basic) stood at -$7.75 in 2021, then advanced by 29.28% to -$5.48 in 2022, then surged by 35.23% to -$3.55 in 2023, then advanced by 6.09% to -$3.34 in 2024, then slumped by 105.98% to -$6.87 in 2025.
- Business Quant data shows LRMR's EPS (Basic) at -$6.87 in Q4 2025, -$0.65 in Q3 2025, and -$0.45 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - | 0.00 |
| 2 | Nanobiotix | 1,914.07 Bn | 1,914.01 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | 0.00 |
| 4 | BeOne Medicines | 468.11 Bn | 463.32 Bn | 1.35 Bn | 0.16 |
| 5 | Vertex Pharmaceuticals | 122.48 Bn | 115.23 Bn | 2.59 Bn | 4.06 |
| 6 | Regeneron Pharmaceuticals | 70.30 Bn | 61.55 Bn | 3.31 Bn | 6.99 |
| 7 | Belite Bio | 62.77 Bn | 62.77 Bn | - | 0.00 |
| 8 | Argenx Se | 55.66 Bn | 50.47 Bn | 1.41 Bn | 7.59 |
| 9 | Alnylam Pharmaceuticals | 37.42 Bn | 34.41 Bn | 959.66 Mn | 1.55 |
| 10 | Larimar Therapeutics | 36.52 Mn | -100.33 Mn | - | -6.87 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -6.87 |
| Sep 30, 2025 | -0.65 |
| Jun 30, 2025 | -0.45 |
| Mar 31, 2025 | -0.58 |
| Dec 31, 2024 | -3.34 |
| Sep 30, 2024 | -0.40 |
| Jun 30, 2024 | -0.54 |
| Mar 31, 2024 | -0.52 |
| Dec 31, 2023 | -3.55 |
| Sep 30, 2023 | -0.40 |
| Jun 30, 2023 | -0.38 |
| Mar 31, 2023 | -0.22 |
| Dec 31, 2022 | -5.48 |
| Sep 30, 2022 | -0.49 |
| Jun 30, 2022 | -0.61 |
| Mar 31, 2022 | -0.95 |
| Dec 31, 2021 | -7.75 |
| Sep 30, 2021 | -1.08 |
| Jun 30, 2021 | -1.37 |
| Mar 31, 2021 | -1.36 |